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ORIGINAL ARTICLEIL-1beInduced Protection of Keratinocytes
against Staphylococcus aureus-Secreted
Proteases Is Mediated by Human
b-Defensin 2
Bingjie Wang1,4, Brian J. McHugh1,4, Ayub Qureshi1,4, Dominic J. Campopiano2, David J. Clarke2,
J. Ross Fitzgerald3, Julia R. Dorin1, Richard Weller1 and Donald J. Davidson1Atopic dermatitis (AD) is a common chronic inflammatory skin disease that results in significant morbidity.
A hallmark of AD is disruption of the critical barrier function of upper epidermal layers, causatively linked
to environmental stimuli, genetics, and infection, and a critical current target for the development of new
therapeutic and prophylactic interventions. Staphylococcus aureus is an AD-associated pathogen producing
virulence factors that induce skin barrier disruption in vivo and contribute to AD pathogenesis. We show, using
immortalized and primary keratinocytes, that S. aureus protease SspA/V8 is the dominant secreted factor
(in laboratory andAD clinical strains of S. aureus) inducing barrier integrity impairment and tight junction damage.
V8-induced integrity damage was inhibited by an IL-1bemediated mechanism, independent of effects on claudin-
1. Induction of keratinocyte expression of the antimicrobial/host defense peptide human b-defensin 2 (hBD2) was
found to be the mechanism underpinning this protective effect. Endogenous hBD2 expression was required and
sufficient for protection against V8 protease-mediated integrity damage, and exogenous application of hBD2 was
protective. This modulatory property of hBD2, unrelated to antibacterial effects, gives new significance to the
defective induction of hBD2 in the barrier-defective skin lesions of AD and indicates therapeutic potential.
Journal of Investigative Dermatology (2017) 137, 95e105; doi:10.1016/j.jid.2016.08.025INTRODUCTION
Atopic dermatitis (AD) is a common relapsing inflammatory
skin disease affecting 15e20% of children (Asher et al., 2006)
and 2e10% of adults (Bieber, 2008) worldwide (<10.7% and
10.2%, respectively, in the United States) (Shaw et al., 2011;
Silverberg and Hanifin, 2013) with significant morbidity. The
disease is characterized by chronic, inflamed, itchy lesions,
typically on the face, scalp, and limbs. A key hallmark of AD is
disruption of upper epidermal layer barrier function, causa-
tively linked to environmental stimuli, genetics (e.g., FLG
mutations), and infections (Bieber, 2008).
AD lesions are particularly susceptible to infection with
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article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).S. aureus is found on the skin of less than 30% of healthy
individuals, mainly in intertriginous areas (Park et al., 2013).
However, 75e100% of AD patients have S. aureus on their
lesional skin, and 30e100% of AD patients have S. aureus on
their nonlesional skin (Breuer et al., 2002; Gong et al., 2006;
Park et al., 2013). S. aureus secrete a range of virulence
factors, including extracellular toxins and proteases, that
contribute to disease pathogenesis (Nakamura et al., 2013).
Serine protease A (SspA), also known as V8 protease,
is a well-characterized extracellular protease widely
expressed among different S. aureus strains (Drapeau et al.,
1972; Kolar et al., 2013). The pathogenic effect of V8 pro-
tease has been shown in vivo, damaging murine skin integrity
via effects on stratum corneum (Hirasawa et al., 2010;
Ohnemus et al., 2008). Although the targets for
V8-mediated damage remain unclear, S. aureus extracel-
lular proteases can cleave tight junction (TJ) proteins,
including claudins, occludin and ZO-1, and des-
mogleins (Hirasawa et al., 2010; Ohnemus et al., 2008),
aggravating skin barrier dysfunction. The capacity of pro-
teases to induce barrier dysfunction is proposed as a key
driving force in the initiation and exacerbation of AD (Takai
and Ikeda, 2011). Thus, understanding the host factors that
maintain barrier function is a priority in developing thera-
peutic approaches.
AD is also characterized by the altered expression of
antimicrobial/host defense peptides (HDPs), including
members of the b-defensin family. b-Defensins human
b-defensin (hBD) 2 and hBD3 are induced by skin wounding
and inflammatory stimuli and are highly expressed inestigative Dermatology. This is an open access
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96inflamed psoriatic skin lesions. In contrast, b-defensins are
present at significantly lower levels in the inflamed skin
lesions from individuals with AD (Ong et al., 2002). Although
some b-defensin induction is observed in AD lesions
compared with nonlesional skin (Harder et al., 2010),
impaired b-defensin induction and/or release in AD is pro-
posed to result from the effects of T helper type 2 cytokines
and to be insufficient to protect against infection. The
expression of HDPs in psoriasis and AD correlates with sus-
ceptibility to infection (Breuer et al., 2002; Schauber and
Gallo, 2009), suggesting a key microbicidal role. However,
these HDPs also have a wide range of modulatory activities,
raising the possibility of additional roles in skin host defense
(Cox et al., 2014).
Here we show that V8 is the dominant factor in S. aureus-
mediated keratinocyte barrier integrity damage, that IL-1b
can induce keratinocyte production of factors with potent
protective activity, and that hBD2 is required and sufficient
for this protection. These data show a protective function for
the antimicrobial HDP hBD2, informing potential therapeutic
approaches to prevent S. aureus-mediated aggravation of skin
barrier dysfunction in AD.
RESULTS
S. aureus-secreted proteases damage keratinocyte
barrier integrity
The effects of secreted S. aureus proteases were examined in
an in vitro monolayer damage assay, using HaCaT keratino-
cyte cells grown to confluency (Figure 1aef). Application of
bacterial supernatant from two different wild-type strains of
S. aureus (8325-4 and USA300 JE2) produced visible areas of
integrity damage (Figure 1b and c). No damage was observed
in media-only controls (Figure 1a). Significantly less damage
occurred when supernatants from mutant strains of S. aureus
deficient in serine proteases SspA, SspB, and SspC (strain
LES22 [Shaw et al., 2004]) or mutated to specifically delete
SspA/V8 protease (strain USA300 DV8 [Fey et al., 2013])
were applied, compared with parent strain 8325-4
(Figure 1def). These data show a model of barrier integrity
damage, induced by S. aureus-secreted proteases and
requiring V8 protease.
S. aureus SspA/V8 damages barrier integrity without causing
cell death
To establish whether V8 protease was sufficient to induce
barrier integrity damage in the absence of other S. aureus-
secreted factors, HaCaT cells were treated with recombinant
V8 protease for 24 hours. Integrity damage was observed in a
concentration-dependent manner (Figure 2aec), with a
phenotype similar to that observed using bacterial superna-
tant. Significant damage was observed at 3 mg/ml of V8, a
concentration previously equated to protease levels found at
S. aureus-colonized sites of AD patients (Miedzobrodzki
et al., 2002). Significant and concentration-dependent V8
protease-mediated monolayer damage was also shown
using human primary epidermal keratinocytes (HPEK)
(Figure 2def), but showing a more diffuse integrity disruption
phenotype (Figure 2d and f). These data show that V8 pro-
tease alone is sufficient to induce barrier integrity damage,
both in primary and immortalized keratinocyte cultures.Journal of Investigative Dermatology (2017), Volume 137S. aureus V8 protease has been proposed to cleave TJ
proteins in damaging barrier integrity (Ohnemus et al., 2008).
Consistent with this report, Western blotting of HaCaT kera-
tinocyte lysates showed a significant reduction in claudin-1
after treatment with V8 protease in a dose-dependent
manner (Figure 2g and h).
Measurements of cellular cytotoxicity (lactate dehydroge-
nase release, Figure 2i) or apoptosis (TUNEL staining,
Figure 2j) showed no significant impact of V8 treatment in
either HaCaT or HPEK cells. In contrast, treatment with
staurosporine (as a positive control for apoptosis) induced a
significant level of TUNEL staining in both cell types
(Figure 2h and i) but did not induce the barrier integrity
damage mediated by V8 (data not shown), showing that this
phenotype was not dependent on cell death.
Pretreatment with IL-1b induces protection of keratinocyte
monolayers against S. aureus V8 protease-mediated damage
IL-1b is a key proinflammatory cytokine proposed to modu-
late expression of TJ proteins and to have impaired produc-
tion in AD (Abe et al., 2003; Jakob et al., 1995; Nomura
et al., 2003). To establish whether IL-1b induced protection
against S. aureus proteases, we treated HaCaT cells with IL-
1b for 24 hours and exposed them to 3mg/ml of V8 protease
(Figure 3a) or S. aureus supernatant (Figure 3b). IL-1b expo-
sure induced significant protection against integrity damage
from V8 protease (88% reduction, Figure 3a) and S. aureus
supernatant (99% reduction, Figure 3b) in a concentration-
dependent manner (see Supplementary Figure S1 online).
This was also observed in primary cells exposed to 6mg/ml of
V8 protease (Figure 3c).
Baseline levels of claudin-1 were significantly increased in
HaCaT cells after IL-1b exposure (58% increase, Figure 3d),
compatible with TJ-mediated enhanced protection against
V8-induced integrity damage. However, IL-1b stimulation
did not prevent V8 protease-mediated reduction of claudin-1
levels, with decreases of 53% and 46% (without and with
IL-1b, respectively) induced by 10mg/ml of V8 protease
(Figure 3d). Furthermore, in HPEK cells, claudin-1 was not
significantly affected by pretreatment with IL-1b (Figure 3e),
indicating dependence on alternative or additional IL-
1beinduced mechanisms.
IL-1b treatment of keratinocytes induces expression of a
soluble protective factor
To determine the nature of IL-1beinduced protection against
V8, media transfer studies were conducted between
IL-1betreated keratinocytes and naive cells before V8 expo-
sure (Figure 4a). After 24 hours of exposure to IL-1b, media
was discarded, cells were washed to remove residual IL-1b,
and fresh media was added for 48 hours to generate condi-
tioned media, which was transferred onto naive cells. Both
naive HaCaT and HPEK cells exposed to conditioned media
from IL-1betreated cells (but not from control cells) were
significantly protected against V8 protease (Figure 4a). These
data show that IL-1b induces keratinocyte production of a
secreted, transferrable protective factor.
IL-1b can stimulate expression of hBDs in keratinocytes,
including hBD2 and hBD3 but not hBD1 (King et al., 2002).
HaCaT cell expression of DEFB1, DEFB4, and DEFB103
(encoding hBD1, hBD2, and hBD3, respectively) was therefore
Figure 1. Staphylococcus aureus-secreted proteases damage keratinocyte barrier integrity. HaCaT keratinocyte cultures treated with either (a) media only or
(bee) filtered S. aureus supernatant for 24 hours. Cells are shown by phase contrast microscopy (top row) or Alexa488 phalloidin stained (bottom row). Scale
bar ¼ 400 mm. Representative images from n ¼ 5. (a) Undamaged media-only control. (b, c) Cells treated with (b) wild-type S. aureus strain 8325-4 or (c) the
clinical strain USA300 JE2, showing integrity damage (white arrows). (dee) Cells treated with (d) mutant S. aureus strains LES22 (SspA, -B, and -C deleted) or
(e) USA300 DV8 (specific deletion of V8 protease) showing significantly less integrity damage. (f) Quantitation of integrity damage showing mean  standard
error of the mean for n ¼ 3. *P < 0.05, ***P < 0.001 versus parent strain.
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exposed to IL-1b or to lipoteichoic acid (LTA), lipopolysac-
charide (LPS), or heat-killed skin commensal Staphylococcus
epidermidis (previously shown to suppress pathogens by
stimulating HDP expression [Lai et al., 2010]). Transcription of
DEFB4 (hBD2) was not detected in unstimulated HaCaT cells,but it was significantly induced by IL-1b stimulation (Figure 4b)
but not by the other stimuli. In contrast, DEFB103 (hBD3)
expression was not detected (data not shown) and, in agree-
ment with published data, DEFB1 (hBD1) expression was not
significantly induced by any of these stimuli (Figure 4b). Ker-
atinocyte production of hBD2 peptide was therefore examinedwww.jidonline.org 97
Figure 2. Staphylococcus aureus serine protease A (SspA/V8) damages keratinocyte barrier integrity without causing cell death. HaCaT or HPEK cells were
exposed to recombinant V8 protease for 24 hours. (aef) Alexa488 Phalloidin staining and damage quantification. Mean  standard error of the mean, n ¼ 6.
***P < 0.001 versus control. Scale bar ¼ 400 mm. Arrows indicate damage. (g, h) Representative HaCaT lysate claudin-1 and b-actin Western blots and
quantification. Mean  standard error of the mean for n ¼ 3. **P < 0.01, ***P < 0.001 versus control. (i, j) Quantification of HaCaT (n ¼ 3) or HPEK (n ¼ 4)
(i) lactate dehydrogenase release and (j) TUNEL staining, 1 mmol/L staurosporine used as TUNEL positive control. Mean  SEM. *P < 0.05, ***P < 0.001 versus
control. HPEK, human primary epidermal keratinocyte; LDH, lactate dehydrogenase; M, mol/L; NS, not significant; Staur, staurosporine.
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Figure 3. Pretreatment with IL-1b protects keratinocytes from V8 protease-mediated damage. (a, b, d) HaCaT or (c, e) HPEK cells were treated with IL-1b
(100 ng/ml) or media only (control) for 24 hours, then exposed to (a, c, d) recombinant V8 protease or (b) S. aureus strain 8325-4 supernatant or (e) left untreated
for 24 hours. (a, b, c) Integrity damage was quantified. Data show mean  standard error of the mean for (a) n¼ 8 or (b, c) n ¼ 3. **P < 0.01, ***P < 0.001 versus
control. (d, e) Western blot quantitation of claudin-1 normalized to control. Data show mean  standard error of the mean for (d) n ¼ 5 or (e) n ¼ 3. **P < 0.01,
***P < 0.001 for V8-treated versus untreated samples; ##P < 0.01 for IL-1betreated versus untreated controls. HPEK, human primary epidermal keratinocyte.
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IL-1b (6-fold increase, to approximately 300 pg/ml), but not to
LTA or LPS (Figure 4c). Heat-killed S. epidermidis also stimu-
lated hBD2 release (9-fold increase), despite not affecting
DEFB4 transcription. Production of hBD2 correlated with
protection against V8-mediated damage, with significant pro-
tection observed in cells treated with IL-1b or heat-killed
S. epidermidis but not LTA or LPS (Figure 4d).
Given the correlation between hBD2 induction and pro-
tection, hBD2 was assessed as a candidate secreted, protec-
tive factor. A time course of IL-1bemediated hBD2 induction
in HaCaT cells showed a significant increase of secreted
hBD2 at 48e72 hours after treatment with IL-1b (Figure 4e).
These findings are compatible with the time point used in V8
damage and conditioned media transfer studies above
(Figures 3a, 3b, and 4a). Significant induction of hBD2 was
also observed in IL-1bestimulated HPEK cells to approxi-
mately 1,000 pg/ml (9-fold increase, Figure 4f), correlating
with significant protection from V8 damage (Figure 3c).
Keratinocyte hBD2 production is sufficient to protect
against V8 protease-mediated damage
To determine whether hBD2 induction was causatively
associated with protection against V8 protease, a DEFB4
stably overexpressing HaCaT cell line (hBD2 OE) and cor-
responding vector-only control line (VO control) wereconstructed. Constitutive DEFB4 transcription was shown in
hBD2 OE cells without IL-1b stimulation (Figure 5a), and
significant hBD2 peptide secretion was detected (at approx-
imately 100 pg/ml, compared with <20pg/ml in VO control
cells) (Figure 5b). Correspondingly, hBD2 OE cells were
significantly protected against V8 protease compared with
VO control cells (Figure 5c). In addition, transfer of condi-
tioned media from hBD2 OE cells, but not from VO control
cells, significantly protected naive HaCaT cells against V8
protease-mediated damage (Figure 5d). These data show that
constitutive endogenous hBD2 expression, in the absence of
IL-1b, is sufficient to replicate the IL-1bemediated protective
phenotype against V8-induced integrity damage.
Claudin-1 levels were also assessed in hBD2 OE
(Figure 5e). V8 mediated significant reduction in claudin-1
levels in hBD2 OE and VO controls, but in contrast to
IL-1b stimulation of HaCaT cells (Figure 3d), constitutive
endogenous hBD2 expression did not increase claudin-1.
These data confirm that hBD2-mediated protection is not a
result of increased claudin-1 expression.
Keratinocyte hBD2 production is required for
IL-1bemediated protection against V8 protease-induced
damage
To establish whether hBD2 expression was required for IL-
1bemediated protection against V8 protease-inducedwww.jidonline.org 99
Figure 4. IL-1b treatment induces the
expression of hBD2 in keratinocytes,
a soluble factor that protects against
V8 protease-mediated damage. (a)
HaCaT (n ¼ 9) or HPEK (n ¼ 3) cells
treated with conditioned media
(transferred from control or IL-1b
[100 ng/ml] pretreated cells) were
exposed to recombinant V8 protease
for 24 hours before quantification of
damage. (bef) HaCaT or HPEK cells
treated for 24 hours or (e) over a time
course with control (media only),
IL-1b (100 ng/ml), LTA (10 mg/ml),
LPS (5 mg/ml), or heat-killed
Staphylococcus epidermidis, then
assessed by (b) real-time reverse
transcriptase PCR for expression of
DEFB4, DEFB1, (c, e, f) ELISA for
hBD2, and (d) quantification of V8-
induced damage. Data show mean 
standard error of the mean. *P < 0.05,
**P < 0.01, ***P < 0.001 versus
control. CM, conditioned media;
HKSE, heat-killed S. epidermidis;
HPEK, human primary epidermal
keratinocyte; LPS, lipopolysaccharide;
LTA, lipoteichoic acid; NS, not
significant.
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hBD2 small hairpin RNA (shRNA) knockdown keratinocyte
cell lines (DEFB4 shRNA 1 and 2) and a nontargeting control
shRNA line were generated. hBD2 knockdown was verified
by ELISA, shown by failure to induce hBD2 in response to
IL-1b in either DEFB4 shRNA line, with levels significantlyJournal of Investigative Dermatology (2017), Volume 137(w80%) lower than in the control (Figure 5f). Both DEFB4
shRNA lines showed significant impairment of IL-
1bemediated protection against V8-induced monolayer
damage compared with the nontargeting shRNA control line
(Figure 5g). These data show that IL-1beinduced endogenous
hBD2 expression is required for this protective phenotype.
Figure 5. hBD2 is sufficient and necessary to protect against V8 protease-mediated damage. (aee) hBD2 overexpressing (hBD2 OE) and vector only (VO
control) HaCaT or naive HaCaT preincubated with CM or (f, g) DEFB4 shRNA-knockdown and control shRNA HaCaT lines  IL-1b prestimulation (100 ng/ml,
24 hours), assessed by (a) DEFB4 quantitative real-time reverse transcriptaseePCR (n ¼ 3), (b, f) hBD2 ELISA (n ¼ 5e7), (c, d, g) V8-mediated damage
quantification (n ¼ 3e4), and (e) quantified Western blot  V8 pre-exposure (3 mg/ml, 24 hours). (h, i) HaCaT or HPEK pretreated with distilled water,
recombinant (3 mg/ml), scrambled (h: 3 mg/ml, i: 6 mg/ml), or synthetic hBD2 (h: 3 mg/ml, i: 6 mg/ml) 24 hours before V8 (h: 24 hours, 3 mg/ml; i: 48 hours,
6 mg/ml). n ¼ 3e5. Mean  standard error of the mean. *P < 0.05, **P < 0.01, ***P < 0.001. CM, conditioned media; hBD, human b-defensin; HPEK, human
primary epidermal keratinocyte; OE, overexpressing; Recomb., recombinant; Scramb., scrambled; shRNA, small hairpin RNA; Synth, synthetic; VO, vector only.
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protease-mediated damage
Having established that induction of endogenous hBD2
expression is protective against V8 protease-induced
damage, the therapeutic potential of exogenously applied
peptide was determined. Addition of either purified recom-
binant hBD2 or chemically synthesized hBD2 (but not a
scrambled sequence version of the peptide or vehicle control)
to unstimulated keratinocytes before V8 protease exposure
significantly protected HaCaT cells (Figure 5h) and HPEKcells (Figure 5i) against damage. These data show that
exogenously applied hBD2 can reconstitute the protective
phenotype against V8 protease and raise the possibility of
therapeutic applications.
DISCUSSION
The pathogenesis of AD and the role of innate host defense-
mediated protection of epidermal integrity in AD remains
incompletely understood. However, defects in epidermal
barrier function in AD are highly associated with dry skin andwww.jidonline.org 101
B Wang et al.
hBD2 Protects Skin Barrier in Atopic Dermatitis
102hyperactive immune response to allergens (Cork et al., 2006;
Sabin et al., 2012). In addition, recent clinical trials show that
restoring and maintaining barrier integrity is critical in pre-
venting AD onset in neonates (Horimukai et al., 2014;
Simpson et al., 2014), confirming the fundamental impor-
tance of epidermal integrity. The capacity of proteases to
induce barrier dysfunction is proposed as a key driving force
in AD initiation and exacerbation (Takai and Ikeda, 2011).
We therefore hypothesized that innate host defense against
proteolytic virulence factors produced by the common AD
skin pathogen S. aureus may be vital to maintaining barrier
function.
To determine the impact of bacterial proteases on kera-
tinocyte function, the effects of S. aureus-conditioned media
(in the absence of live bacteria) were evaluated using
immortalized and primary keratinocyte monolayer culture
models. These studies generated an integrity damage model
and established that the primary S. aureus-secreted factor
was V8 protease (i.e., SspA). V8 exposure generated discrete
“holes” in HaCaT monolayers without inducing cell death;
experimental induction of apoptosis did not replicate this
phenotype. In live cell imaging, rapid contraction from the
center of such holes was observed (data not shown), with a
concentrated band of phalloidin-positive signal seen around
the “hole” edge (Figure 2c), suggestive of central foci of TJ
failure and cell retraction from that point. In keeping with
this, we show V8-cleavage of claudin-1 in this model.
Primary keratinocytes were less sensitive to V8, perhaps
because of higher baseline hBD2 production, requiring
higher concentration of protease to reproducibly induce
significant damage, but then undergoing a more cata-
strophic failure of monolayer integrity. These findings are
compatible with previously shown V8-mediated damage to
murine skin integrity in vivo (Hirasawa et al., 2010;
Ohnemus et al., 2008), confirming the validity of this
model and significance of this protease for keratinocyte
barrier integrity.
A wide range of factors can promote keratinocyte defense
against the deleterious effects of pathogens, including cyto-
kines released by immune cells (e.g. IL-1b, IL-22), and bac-
terial factors such as LPS and LTA (Ganz and Lehrer, 1998; Liu
et al., 2002; O’Neil et al., 1999). Evaluation of host and
bacterial inflammatory agonists established that IL-1b, pre-
viously shown to modulate TJ protein expression and be
diminished in AD (Abe et al., 2003; Jakob et al., 1995;
Nomura et al., 2003), induced protection of keratinocytes
against frank V8-mediated integrity damage. This effect was
not observed after stimulation with LPS or LTA but was also
generated by exposure to heat-killed S. epidermidis.
Although IL-1b up-regulated claudin-1 expression in HaCaT
cells, claudin-1 degradation was not inhibited, and protec-
tion was independent of claudin-1 levels in primary cells.
These data indicated an alternative mechanism of protection,
shown to be via secretion of an unidentified, transferrable
innate host factor.
In contrast to patients with psoriasis, individuals with AD
have impaired expression of HDPs, in particular hBD2,
hBD3, and the cathelicidin LL-37 in inflamed lesions
(Gambichler et al., 2008; Ong et al., 2002). Although several
HDPs appear to have impaired expression in AD, hBD2 isJournal of Investigative Dermatology (2017), Volume 137reported to have the closest correlation with AD severity and
skin infections (Clausen et al., 2013). In addition to direct
antibacterial and antiviral properties (Gwyer Findlay et al.,
2013; Lehrer et al., 1989; Mookherjee and Hancock,
2007), hBD2 also has modulatory effects on both the innate
and adaptive immune system and promotes wound healing
(Beaumont et al., 2014; Choi et al., 2012; Semple and Dorin,
2012; Yeung et al., 2011). Modulatory functions of HDP have
key roles in the pathogenesis of psoriasis (Morizane and
Gallo, 2012) and rosacea (Yamasaki et al., 2007) but are
undescribed in AD. Unlike hBD1, which is constitutively
expressed in skin, hBD2 and hBD3 expression are induced
by proinflammatory cytokines, including IL-1b and bacterial
products from commensals such as S. epidermidis (via a toll-
like receptor 2emediated pathway [Lai et al., 2010] as well
as skin wounding [Ganz and Lehrer, 1998; Liu et al., 2002;
O’Neil et al., 1999]). Induction of hBD2 in our keratinocyte
models was found to correlate with the inducible protection
phenotype in response to IL-1b and heat killed S. epi-
dermidis. Genetic manipulation of hBD2 expression was
then utilized to show that hBD2 production is the mechanism
underpinning IL-1bemediated protection against V8-induced
barrier integrity damage. Keratinocyte production of hBD2
was required and sufficient (in the absence of IL-1b) for the
protection phenotype, which was independent of effects on
claudin-1 expression or degradation.
The cellular consequences of hBD2 production that lead to
protection against V8 remain to be determined and are the
subject of ongoing studies. Although hBD2, at concentrations
of 7 mg/ml and above, can promote cell proliferation and
tissue remodeling, and can induce matrix metalloproteinases
and tissue inhibitors of metalloproteinase (Li et al., 2006),
overexpression of hBD2 in our study did not affect cell pro-
liferation (data not shown). b-Defensins are not characterized
as exhibiting direct anti-protease activity; however, this has
been reported for neutrophil a-defensins (Van Wetering et al.,
1997) and other antimicrobial proteins including SLPI and
elafin (Moreau et al., 2008; Williams et al., 2006). Further-
more, hBD2 and hBD3 contain an evolutionarily conserved
“gamma-core” structural motif sufficient for antimicrobial
activity and, interestingly, also for resistance to proteolytic
degradation (Nigro et al., 2015). The significance of these
structural features with respect to protection against V8 pro-
tease remains to be determined. Alternatively, hBD2 may
induce keratinocyte production of anti-proteases, TJ proteins
other than claudin-1, or alternative factors. Recent studies
have shown that exposure to high concentrations of exoge-
nously applied hBD3 and LL-37 can selectively increase
keratinocyte expression of claudins and occludin to enhance
TJ function (Akiyama et al., 2014; Kiatsurayanon et al., 2014).
However, in keeping with our study, hBD2 was found not to
enhance TJ function, and the consequence of these HDP-
mediated effects on susceptibility to bacterial proteases was
not determined. hBD3 was not expressed in our models, nor
was LL-37 induced by IL-1b (data not shown) in our kerati-
nocyte models. Despite an inability to enhance TJ function,
we show that therapeutic application of exogenous recom-
binant or synthetic hBD2 (but not a scrambled sequence
peptide control) could protect keratinocytes from V8-
mediated barrier integrity damage without induction of
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development of therapies.
Because of the early onset and chronic relapsing nature of
AD, safe, long-term therapeutics are required. However, the
current principal treatment, topical corticosteroid, can have
detrimental effects (e.g., perioral dermatitis and skin atrophy),
and individuals becoming refractory to topical application
require systemic treatment, with potentially severe adverse
effects (Schakel et al., 2014). Development of interventions
to restore barrier integrity was recently identified by
researchers, clinicians, patients, and policymakers as a top-10
translational dermatology research priority in an e-Delphi ex-
ercise (Healy et al., 2015). Our data show that interventional
approaches aimed at promoting endogenous hBD2 expression
and/or the therapeutic application of hBD2 (or synthetic ana-
logues) may have the potential to enhance/restore skin barrier
integrity, protect against S. aureus V8 protease-mediated
damage, and reduce reliance on corticosteroids.
MATERIAL AND METHODS
Antibodies and real-time PCR reagents are listed in Supplementary
Table S1 online.
Bacterial strains
S. aureus strains 8325-4, LES22, USA300 JE2, and USA300 DV8 were
a kind gift from Simon Foster and Lindsay Shaw (University of Shef-
field), and S. epidermidis strain 9759 was from J. Ross Fitzgerald
(University of Edinburgh). Bacteria were grown in 10 ml of tryptic soy
broth (S. aureus) (with 5mg/ml erythromycin for LES22 and USA300
DV8) or luria broth (S. epidermidis) for 16 hours at 37 C with
shaking. Bacteria were harvested at an optical density (600 nm) of
1.4, pelleted for 10 minutes at 5,000g, resuspended in 1 ml of media,
and either supernatant clarified with a 0.22-mm filter and concen-
trated in an RC1010 centrifugal evaporator (Jouan, Winchester, U.K.)
(S. aureus) or bacteria heat killed at 70 C for 30 minutes before use at
an effective multiplicity of infection of 240:1 (S. epidermidis).
Cell culture
Human keratinocyte line HaCaT (CLS GmbH, Eppelheim, Germany)
was maintained in DMEM (DMEM/F-12, Gibco, Loughborough,
UK) with 10% volume-to-volume fetal bovine serum and 1% peni-
cillin 100IU/mlestreptomycin 10mg/mle2mmol/L L-glutamine (GE
Healthcare, Buckinghamshire, UK). HPEKp0.5 cells (CELLnTEC,
Bern, Switzerland) were maintained in CnT57 media (CELLnTEC)
and replaced with CnT02 media (CELLnTEC) at 100% confluency.
All cells were cultured at 37 C, 95% relative humidity, and
5% CO2.
To create hBD2 OE and VO control HaCaT lines, TrueORF Gold
pCMV6-DEFB4 gene expression clone or pCMV6 vector-only
backbone (OriGene Technologies, Rockville, MD) were transfected
with Lipofectamine 2000 (Life Technologies, Renfrew, UK), followed
by selection with 500 mg/ml of G418 (Life Technologies). Individual
hBD2 shRNA knockdown lines were made by stable transfection of
HaCaT cells with pLKO.1 lentiviral shRNA target gene set targeting
DEFB4A (GE Healthcare, catalogue no. RHS4533) or pLKO.1 vector
containing a scrambled nontargeting shRNA hairpin (Addgene
plasmid 1864, Cambridge, MA [Sarbassov et al., 2005]), followed by
5mg/ml puromycin selection.
Keratinocyte monolayer damage assay
HaCaT or HPEK cells were seeded at 3  105 cells/well in 12-well
plate at 37 C until monolayer formation (48e72 hours). Mediawas removed, cells washed twice with phosphate buffered saline,
and serum-free media added. As required, monolayers were stimu-
lated with 100ng/ml IL-1b (Peprotech, Rocky Hill, NJ), 10mg/ml of
LTA (InvivoGen, San Diego, CA), 5mg/ml of LPS (InvivoGen), or heat-
killed S. epidermidis or pretreated with 3 mg/ml of recombinant
hBD2 peptide (ProSpec, East Brunswick, NJ), custom synthetic
hBD2 (GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP) or
scrambled (IGKILKHVGLSGYCKGDCTRGPCGPFVITCCQCRKPPPA
KT) peptides (Almac, East Lothian, UK) for 24 hours. Subsequently,
recombinant S. aureus V8 protease (Worthington, Lakewood, NJ) was
added as indicated. Cell supernatant was collected for ELISA, and
protein lysate or RNAwas extracted from treated cells.
Damage was assessed from images acquired using an EVOS fl
digital inverted microscope (ThermoFisher Scientific, Paisley, UK).
Representative images (>3 per condition) were analyzed using
ImageJ software (National Institutes of Health, Bethesda, MD),
quantifying breaks in the keratinocyte monolayer, with damage
expressed as a percentage loss of monolayer integrity. For phalloidin
staining, treated keratinocyte monolayers were fixed in 4% PFA,
washed in phosphate buffered saline, and incubated with Alexa488
phalloidin (Life Technologies) per the manufacturer’s instructions.
SDS-PAGE and Western blot
Cell lysates were prepared using M-PER Mammalian Protein
Extraction Reagent (Life Technologies), equalized, and boiled at
96 C for 5 minutes in loading/reducing buffer. Next, 20-mg samples
were electrophoresed on 4e12% SDS-PAGE Novex gels (Life
Technologies), transferred to 0.2-mmol/L nitrocellulose membrane
(Life Technologies) using Towbin buffer, blocked with 5% milk in
Tris-buffered saline þ 0.1% Tween-20, (Sigma Aldrich, Dorset, UK)
and incubated with antibodies as detailed. Western blots were
visualized and quantitated using the LI-COR Biosciences (Lincoln,
NE) Odyssey system.
Real-time PCR
RNA was extracted from keratinocytes using RNeasy mini kit
(Qiagen, Manchester, UK) and reverse transcribed to cDNA using
the TaqMan RT-PCR kit (Life Technologies). StepOne Real Time PCR
machine (ThermoFisher Scientific) and 48-well MicroAmp optical
plates (Life Technologies, Renfrew, UK) were used for amplification
reactions. Copy number was analyzed according to McNeilly et al.
(2008). Standard curves were performed using plasmids for DEFB1,
DEFB4 (Origene #SC116851, RC219487), and DEFB103 (generated
by J. Dorin).
ELISA
hBD2 ELISA development kit (Peprotech) was used to determine
hBD2 peptide levels in culture media per the manufacturer’s pro-
tocol. Peptide levels were determined in neat supernatant in
triplicate.
Cytotoxicity and apoptosis measurements
Lactate dehydrogenase release was assayed using the lactate dehy-
drogenase cytotoxicity detection kit (Abcam, Cambridge, UK).
Absorbance was measured at 450 nm, with a reference wavelength
of 650 nm. Cytotoxicity was calculated using the formula: cytotox-
icity (%) ¼ (test sample e low control [untreated cells])/(high control
[lysed cells] e low control)  100. Apoptosis was assessed by
TUNEL assay using the In Situ Cell Death Detection Kit (Roche,
Basel, Switzerland). Cells were treated with the conditions indicated
and compared with treatment with staurosporine at 1 mmol/L for 3
hours as a positive control.www.jidonline.org 103
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104Statistical analysis
Statistical analysis was performed using the GraphPad PRISM5 sta-
tistical package (GraphPad software, La Jolla, CA) by Student t test
(Figures 1f and 2i (HPEK), 4a and f, and 5aed and gei), one-way
analysis of variance with Dunnett multiple comparison posttest
(Figures 2a, d, h, i [HaCaT] and j; 3 aec and e; and 4 bee) or two-
way analysis of variance with Bonferroni posttest (Figures 3d and 5e
and f). P-values below 0.05 were considered significant.
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